Browse News
Filter News
Found 4,901 articles
-
The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019
1/15/2019
Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported that data from four abstracts—including three oral presentations—were accepted for presentation at the Transplantation & Cellular Therapy (TCT) Meetings
-
The Leukemia & Lymphoma Society (LLS) Continues to Drive Progress to Cancer Cures
1/15/2019
Groundbreaking advances that harness the body's immune system to attack cancer cells are set to continue, as well as significant focus on new therapies for children with cancer.
-
Immunocore Names David Berman as Head of R&D
1/15/2019
Leading figure in immuno-oncology strengthens Immunocore’s senior leadership team
-
Merck’s KEYTRUDA® (pembrolizumab) Reduced Risk of Death by 31 Percent Compared to Chemotherapy in Previously Treated Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Expressed PD-L1 (CPS ≥10)
1/14/2019
Results from Phase 3 KEYNOTE-181 Trial to be Presented at 2019 Gastrointestinal Cancers Symposium (ASCO GI)
-
Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
1/9/2019
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today provided a pipeline update and announced its 2019 financial guidance at the 37th annual JP Morgan Healthcare Conference.
-
Cellular Biomedicine Group Initiates Patient Recruitment for Clinical Trial in B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Targeting Multiple Myeloma (MM)
1/9/2019
Cellular Biomedicine Group Inc. today announces the initiation of patient recruitment to support the study of anti-BCMA CAR-T therapy targeting relapsed and refractory Multiple Myeloma in China.
-
Koneksa Health Announces Addition to Scientific Advisory Board
1/8/2019
Renowned oncologist William A. Wood, MD, MPH, of UNC Lineberger joins scientific advisors
-
Tarrytown, NY-based Regeneron Pharmaceuticals and Paris-based Sanofi restructured a 2015 agreement to develop immuno-oncology (I/O) treatments. That deal was scheduled to wrap in 2020, but the revision adds two clinical-stage bispecific antibodies to the collaboration.
-
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
1/7/2019
Companies select two clinical-stage bispecific antibodies for ongoing collaboration
-
Celgene Corporation Announces 2019 Financial Guidance and Key Milestones
1/7/2019
Company achieved its latest full-year 2018 guidance; will report Q4 2018 results on January 31, 2019
-
Gamida Cell Announces 2019 Goals and Provides Company Update
1/7/2019
Patient Enrollment in Phase 3 Study of NiCord® on Track for Completion in Second Half of 2019; Topline Results Expected in First Half of 2020
-
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
1/7/2019
Regeneron Pharmaceuticals, Inc. will provide a strategic business update to the investor community at the 37th Annual J.P. Morgan Healthcare Conference
-
Over the past decade, BMS has been no stranger to flexing its M&A muscle. The company made numerous focused-acquisitions that have positioned itself as a leader in oncology. BMS CEO Giovanni Caforio noted that the massive deal for Celgene is another piece to that puzzle.
-
The JP Morgan Healthcare Conference, being held from January 7 through 10 at the Westin St. Francis Hotel in San Francisco, is one of the premier, possible the premier, conferences for the biopharmaceutical industry.
-
Machavert Pharmaceuticals to Present at Biotech Showcase™, 2019 in San Francisco
1/4/2019
Machavert Pharmaceuticals announced today that it will present at Biotech Showcase™ 2019, to be held January 7–9, during the most important week in healthcare at the Hilton San Francisco Union Square.
-
This morning, Osaka, Japan-based Takeda struck deals with Memorial Sloan Kettering Cancer Center, Noile-Immune Biotech Inc. and Crescendo Biologics.
-
EvaluatePharma and Vantage recently released their Vantage 2019 Preview which looks at the current year’s biopharma market and makes projections about the upcoming year.
-
Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco
1/3/2019
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) announced today that Sandesh Seth, Actinium's Chairman and Chief Executive Officer will present at the Biotech Showcase™ 2019 being held on January 7-9.
-
IGM Biosciences Appoints Misbah Tahir as Chief Financial Officer
1/3/2019
Mr. Tahir Brings More Than 20 Years of Financial and Strategic Planning Experience
-
Marker Therapeutics Provides Updates of its Lead Clinical Programs
1/3/2019
Reports clinical data updates with MultiTAA T cells in lymphoma, multiple myeloma and acute lymphoblastic leukemia